Research map: Long-term persistence of humoral immunity after SARS-CoV-2 mRNA booster vaccination in SARS-CoV-2-naïve individuals

Back to the article

Papers in this map

  1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China · Chaolin Huang · 2020 · 52006 citations · Cited by this paper
  2. Descriptive comparison of COVID-19 and influenza in Asia-Pacific in 2024–2025 · 2026 · Related
  3. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report · Lisa A. Jackson · 2020 · 3520 citations · Cited by this paper
  4. Hepatitis B vaccine-induced immunity among hill tribe and stateless children in northern Thailand · 2026 · Related
  5. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates · Edward E. Walsh · 2020 · 2748 citations · Cited by this paper
  6. Immunogenicity and protective efficacy of inactivated and vectored H9N2 vaccines in broilers with maternally derived antibodies · 2026 · Related
  7. Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA · Katalin Karikó · 2005 · 2743 citations · Cited by this paper
  8. A novel in silico construction of a DNA vaccine expressing broad-spectrum CD8 T-cell multi-epitope antigen against high-risk human papillomavirus infection · 2026 · Related
  9. Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability · Katalin Karikó · 2008 · 1958 citations · Cited by this paper
  10. Association of body mass index with COVID-19 risk and vaccine effectiveness in children · 2026 · Related
  11. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months · Einav G. Levin · 2021 · 1832 citations · Cited by this paper
  12. Measuring vaccination attitudes: validated methods and predictive models with evidence from Covid-19 research · 2026 · Related
  13. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study · Jeffrey S. Weber · 2024 · 873 citations · Cited by this paper
  14. Addressing the social nature of vaccination hesitancy in humanitarian immunization programs. An experience of developing a qualitative assessment tool on vaccination decision making in Médecins Sans Frontières, MSF · 2026 · Related
  15. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 · Nicole A. Doria‐Rose · 2021 · 758 citations · Cited by this paper
  16. Long-term evolution of pneumococcal serotypes linked to invasive diseases in Colombia and potential coverage by new pneumococcal vaccines: An analysis of national surveillance data between 2005-2023 · 2026 · Related
  17. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults · Eleanor M. P. Wilson · 2023 · 503 citations · Cited by this paper
  18. Human papillomavirus (HPV) prevalence and genoprevalence in Jimma town of Southwest Ethiopia: a population-based study · 2026 · Related
  19. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials · Brandon J. Essink · 2023 · 152 citations · Cited by this paper
  20. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase · Komal Srivastava · 2024 · 150 citations · Cited by this paper
  21. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan · Takahiro Kageyama · 2021 · 140 citations · Cited by this paper
  22. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data · Deidre E. Wilkins · 2023 · 118 citations · Cited by this paper
  23. A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults · Mieke Soens · 2025 · 81 citations · Cited by this paper
  24. Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients · Noa Berar Yanay · 2021 · 22 citations · Cited by this paper
  25. Prophylactic vaccines against Epstein–Barr virus · Ling Zhong · 2024 · 14 citations · Cited by this paper
  26. Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study · Timothy Russell · 2024 · 9 citations · Cited by this paper
  27. Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination · Yoshifumi Uwamino · 2023 · 7 citations · Cited by this paper
  28. Estimating the decay of protective antibodies induced by SARS-CoV-2 mRNA vaccination and hybrid immunity · McKenna D. Roe · 2025 · 7 citations · Cited by this paper
  29. Longitudinal immune kinetics of COVID-19 booster versus primary series vaccination: Insight into the annual vaccination strategy · Min Joo Choi · 2024 · 6 citations · Cited by this paper
  30. Incidence and risk factors of SARS-CoV-2 breakthrough infection in the early Omicron variant era among vaccinated and boosted individuals in Chicago · Fabiola M Moreno Echevarria · 2024 · 4 citations · Cited by this paper
  31. Longitudinal antibody titers measured after COVID-19 mRNA vaccination can identify individuals at risk for subsequent infection · Hyeongki Park · 2025 · 4 citations · Cited by this paper
  32. Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020–2022): A retrospective longitudinal SARS-CoV-2 serological surveillance · Vanessa De Pace · 2023 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)